258 related articles for article (PubMed ID: 12534644)
1. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
[TBL] [Abstract][Full Text] [Related]
3. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Pharmacol Toxicol; 1999 Mar; 84(3):143-6. PubMed ID: 10193676
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Floreani M; Palatini P
Clin Pharmacol Ther; 2004 Jan; 75(1):80-8. PubMed ID: 14749694
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
[TBL] [Abstract][Full Text] [Related]
6. Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers.
Swart EL; van der Hoven B; Groeneveld AB; Touw DJ; Danhof M
Br J Clin Pharmacol; 2002 Feb; 53(2):133-9. PubMed ID: 11851636
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
8. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans.
Reichel C; Skodra T; Nacke A; Spengler U; Sauerbruch T
Br J Clin Pharmacol; 1998 Dec; 46(6):535-9. PubMed ID: 9862241
[TBL] [Abstract][Full Text] [Related]
9. The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.
Olkkola KT; Isohanni MH; Hamunen K; Neuvonen PJ
Anesth Analg; 2005 May; 100(5):1352-1356. PubMed ID: 15845683
[TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
11. Effect of erythromycin and rifampicin on monoethylglycinexylidide test.
Bhise SB; Dias RJ
Indian J Pharmacol; 2008 Mar; 40(2):84-6. PubMed ID: 21279172
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.
Thomson AH; Elliott HL; Kelman AW; Meredith PA; Whiting B
J Pharmacokinet Biopharm; 1987 Apr; 15(2):101-15. PubMed ID: 3612496
[TBL] [Abstract][Full Text] [Related]
13. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
[TBL] [Abstract][Full Text] [Related]
14. Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide.
McKindley DS; Boulet J; Sachdeva K; Wang P; Chichester C
Shock; 2002 Mar; 17(3):199-204. PubMed ID: 11900338
[TBL] [Abstract][Full Text] [Related]
15. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Ferrara SD; Tedeschi L; Frison G; Orlando R; Mazzo M; Zordan R; Padrini R; Palatini P
Eur J Clin Pharmacol; 1996; 50(4):305-10. PubMed ID: 8803524
[TBL] [Abstract][Full Text] [Related]
16. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
[TBL] [Abstract][Full Text] [Related]
17. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):120-3. PubMed ID: 15447735
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of lidocaine and its metabolites after prolonged infusion in healthy horses.
Dickey EJ; McKenzie HC; Brown KA; de Solis CN
Equine Vet J; 2008 Jun; 40(4):348-52. PubMed ID: 18267881
[TBL] [Abstract][Full Text] [Related]
19. The monoethylglycinexylidide test for grading of liver cirrhosis.
Fabris L; Jemmolo RM; Toffolo G; Paleari D; Viaggi S; Rigon M; Casagrande F; Lirussi F; Strazzabosco M; Cobelli C; Okolicsanyi L
Aliment Pharmacol Ther; 1999 Jan; 13(1):67-75. PubMed ID: 9892881
[TBL] [Abstract][Full Text] [Related]
20. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
